Abstract
Children are at higher risk for developing post-transplant lymphoproliferative disease (PTLD) than adults. Successful treatment of PTLD following solid organ transplant is a therapeutic challenge due to the patients’ increased toxicity from chemotherapy, increased susceptibility to life-threatening infections, and the necessity to maintain the allograft. Patients who do not tolerate reduction of immune suppression (i.e., graft rejection), or have PTLD that does not respond to immune suppression reduction, require more aggressive therapy and have a much poorer prognosis. We report 39 children with PTLD who failed reduction of immune suppression and were treated with a lowdose chemotherapy regimen of cyclophosphamide (600 mg/m) and prednisone (2 mg/kg per day for 5 days) given every 3 weeks for 6 cycles. The complete remission rate was 82%. Graft survival was 90%. Relapse rate was 22%, with late-onset PTLD (>2 years from transplant) more likely to relapse. Of the seven patients with relapsed PTLD, four were salvaged with “conventional” non-Hodgkin’s lymphoma chemotherapy. The overall 1-year survival for patients treated with low-dose chemotherapy was 86%. The estimated 2-year survival is 73%. This low-dose chemotherapy approach is well tolerated and effective for PTLD in children who fail reduction of immune suppression.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ho M, laffe R, Miller G et al (1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45:719–727
Malatack JJ, Gartner JC, Urbach AH et al (1991) Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 118:667–675
Newell KA, Alonso EM, Whittington PF et al (1996) Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 62: 370–375
Swerdlow SH (1992) Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease. Histopathology 20:373–385
Knowles DM, Cesarman E, Chadburn A et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565
Smir B, Hauke RJ, Bierman PJ et al (1996) Molecular epidemiology of deletion and mutations of the LMPl oncogene of Epstein-Barr virus in posttransplant lymphoproliferative disorders. Lab Invest 75:575–588
Greiner TC, Abou-Elella AA, Smir BN et al (2000) EBNA-1 substrain and p53 mutation analysis in Epstein-Barr virus positive posttransplant lymphoproliferative disorders. Leuk Lymphoma 38:563–576
Hayashi RJ Kraus MD, Patel AL et al (2001) Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 23:14–18
Dotti G, Fiocchi R, Motta T (2000) Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney and liver transplant. Transplantation 69:827–833
Swinnen LJ Mullen GM, Carr TJ et al (1995) Aggressive treatment for postcardiac lymphoproliferation. Blood 86:3333–3340
Nalesnik MA, Makowka, Starzl TE (1988) The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 25:367–472
Leblond V, Sutton L, Dorent R (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 13:961–968
Mamzer-Bruneel M-F, Lome C, Morelon E (2001) Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 18:3622–3632
Gross TG, Hinrichs SH, Winner J et al (1998) Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low dose chemotherapy. Ann Oncol 9:339–340
Okano M, Gross TG (1996) Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am J Hematol 53:111–115
Seemayer, TA, Gross TG, Egeler RM et al (1995) X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 38:471–478
Vosz JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19:389–397
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gross, T.G. (2002). Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive